New genetic and environmental studies of Parkinson's disease have revealed early problems in synaptic function and connectivity indicating that axonal impairment may be an important hallmark in this disorder. Since many studies suggest that axonal dysfunction precedes cell body loss, it is critical to target axons with treatments aimed at preserving "connectivity" as well as to develop and verify "biomarkers" with which to assess disease progression and drug efficacy.

Keywords: axon transport, mitochondria, Wallerian degeneration, MPTP

1. Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 2007;8:663-672.
   
2. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973;20:415-455.
   
3. Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004;318:121-134.
   
4. Bueler H. Mitochondrial dynamics, cell death and the pathogenesis of Parkinson's disease. Apoptosis 2010;15:1336-1353.
   
5. Cai Q, Sheng ZH. Mitochondrial transport and docking in axons. Exp Neurol 2009;218:257-267.
   
6. Cappelletti G, Surrey T, Maci R. The parkinsonism producing neurotoxin MPP⁺ affects microtubule dynamics by acting as a destabilising factor. FEBS Lett 2005;579:4781-4786.
   
7. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003;39:889-909.
   
8. Hasbani DM, O'Malley KL. Wld(S) mice are protected against the Parkinsonian mimetic MPTP. Exp Neurol 2006;202:93-99.
   
9. Hilliard MA. Axonal degeneration and regeneration: a mechanistic tug-of-war. J Neurochem 2009;108:23-32.
   
10. Ikegami K, Koike T. Non-apoptotic neurite degeneration in apoptotic neuronal death: pivotal role of mitochondrial function in neurites. Neuroscience 2003;122:617-626.
    
11. Li Y, Liu W, Oo TF, Wang L, Tang Y, Jackson-Lewis V, Zhou C, Geghman K, Bogdanov M, Przedborski S, Beal MF, Burke RE, Li C. Mutant LRRK2 (R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci 2009;12:826-828.
    
12. Lu B. Mitochondrial dynamics and neurodegeneration. Curr Neurol Neurosci Rep 2009;9:212-219.
    
13. Mack TG, Reiner M, Beirowski B, Mi W, Emanuelli M, Wagner D, Thomson D, Gillingwater T, Court F, Conforti L, Fernando FS, Tarlton A, Andressen C, Addicks K, Magni G, Ribchester RR, Perry VH, Coleman MP. Wallerian degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene. Nat Neurosci 2001;4:1199-1206.
    
14. MacLeod D, Dowman J, Hammond R, Leete T, Inoue K, Abeliovich A. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 2006;52:587-593.
    
15. Miller KE, Sheetz MP. Axonal mitochondrial transport and potential are correlated. J Cell Sci 2004;117:2791-2804.
    
16. Morfini GA, Burns M, Binder LI, Kanaan NM, LaPointe N, Bosco DA, Brown RH, Brown H, Tiwari A, Hayward L, Edgar J, Nave KA, Garberrn J, Atagi Y, Song Y, Pigino G, Brady ST. Axonal transport defects in neurodegenerative diseases. J Neurosci 2009;29:12776-12786.
    
17. Narendra DP, Jin SM, Tanaka A, Suen DF, Gautier CA, Shen J, Cookson MR, Youle RJ. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol 2010;8:e1000298.
    
18. Orimo S, Uchihara T, Nakamura A, Mori F, Kakita A, Wakabayashi K, Takahashi H. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain 2008;131:642-650.
    
19. Press C, Milbrandt J. Nmnat delays axonal degeneration caused by mitochondrial and oxidative stress. J Neurosci 2008;28:4861-4871.
    
20. Raff MC, Whitmore AV, Finn JT. Axonal selfdestruction and neurodegeneration. Science 2002;296:868-871.
    
21. Ren Y, Liu W, Jiang H, Jiang Q, Feng J. Selective vulnerability of dopaminergic neurons to microtubule depolymerization. J Biol Chem 2005;280:34105-34112.
    
22. Saha AR, Hill J, Utton MA, Asuni AA, Ackerley S, Grierson AJ, Miller CC, Davies AM, Buchman VL, Anderton BH, Hanger DP. Parkinson's disease alpha-synuclein mutations exhibit defective axonal transport in cultured neurons. J Cell Sci 2004;117:1017-1024.
    
23. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet 2004;363:1783-1793.
    
24. Sasaki Y, Vohra BP, Lund FE, Milbrandt J. Nicotinamide mononucleotide adenylyl transferase-mediated axonal protection requires enzymatic activity but not increased levels of neuronal nicotinamide adenine dinucleotide. J Neurosci 2009;29:5525-5535.
    
25. Schapira AH, Agid Y, Barone P, Jenner P, Lemke MR, Poewe W, Rascol O, Reichmann H, Tolosa E. Perspectives on recent advances in the understanding and treatment of Parkinson's disease. Eur J Neurol 2009;16:1090-1099.
    
26. Waldmeier P, Bozyczko-Coyne D, Williams M, Vaught JL. Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases. Biochem Pharmacol 2006;72:1197-1206.
    
27. Weihofen A, Thomas KJ, Ostaszewski BL, Cookson MR, Selkoe DJ. Pink1 forms a multiprotein complex with Miro and Milton, linking Pink1 function to mitochondrial trafficking. Biochemistry 2009;48:2045-2052.
    
28. Westerlund M, Hoffer B, Olson L. Parkinson's disease: Exit toxins, enter genetics. Prog Neurobiol 2010;90:146-156.
    
29. Yahata N, Yuasa S, Araki T. Nicotinamide mononucleotide adenylyltransferase expression in mitochondrial matrix delays Wallerian degeneration. J Neurosci 2009;29:6276-6284.
    
30. Yang ML, Hasadsri L, Woods WS, George JM. Dynamic transport and localization of alpha-synuclein in primary hippocampal neurons. Mol Neurodegener 2010;5:9.